Grant RDF

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• 36
• 37
• 38
• 39
• 40
• more...

• A Trial to Improve Surrogate Decision-Making for Critically III Older Adults
• A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT)
• A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT) ("Clinical Study")
• A Website to Teach Children Safety with Dogs: Development and Evaluation
• A Whole-Epigenome Approach to Identifying Novel Targets for Nano-Pharm Memory Enhancement
• A-Z Clinical Trials Unit
• A20 Promotes Glioma Stem Cell Mediated Tumorigenesis
• A5210.04-University of Alabama at Birmingham - VSL 54
• A5272/A5280 Supplemental Funds from Adult Clinical Trials Group
• A5391- Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
• AAAS Fellowship
• AADR Proctor & Gamble Underrepresented Faculty Research Fellowship
• AADR-Anne D. Haffajee Fellowship
• AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,
• AAHPM Y.C. Ho/Helen & Michael Chiang Foundation 2016 Fellowship Grant
• AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia
• AALL0434-Novartis Pharmaceuticals Corporation
• AALL1131 Supplemental PCR
• AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
• AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)
• AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
• AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases
• AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD
• AAML 1031 - Bayer
• AAML1031: One Time EOY, Integrated BIQSFP AAML1031-Echocardiogram Reports and Images
• AANP Neurodegenerative Disease Scholars Program
• AAP School Nurse and Pediatrician Learning Collaborative
• AAV-Based Plasmacytoid Dentritic Cell Cancer Vaccine
• AAV-Mediated Gene Therapy for Metabolic Bone Disease
• Abbott Fund Interventional Fellowship Grant 2017-2018

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• 36
• 37
• 38
• 39
• 40
• more...